Search research articles
Contact Us
Filters
Showing results (151-160 of 236) with videos related to
Page
of 24
Sort By:
Kidney International Reports
|
May 20, 2024
Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
Marie-Julia Ziliotis, Charline Vauchy, Eric Deconinck, et al.
Oncotarget
|
February 10, 2018
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
Francesco Saraceni, Myriam Labopin, Rose-Marie Hamladji, et al.
Transfusion
|
July 29, 2010
Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors
Caroline Marmier-Savet, Fabrice Larosa, Faezeh Legrand, et al.
Haematologica
|
March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation
Nicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
American Journal of Hematology
|
June 13, 2020
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
Arnon Nagler, Myriam Labopin, Jonathan Canaani, et al.
Leukemia
|
November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Blood
|
July 16, 2011
Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation
Fabrice Larosa, Eric Deconinck, Philippe Helias, et al.
American Journal of Hematology
|
July 8, 2018
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation
Maria H Gilleece, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
American Journal of Hematology
|
April 18, 2020
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)
Enrico Maffini, Myriam Labopin, Didier Blaise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2008
Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC
Patrice Chevallier, Mohamad Mohty, Bruno Lioure, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 236) with videos related to
Sort By:
Page
of 24
Kidney International Reports
|
May 20, 2024
Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
Marie-Julia Ziliotis, Charline Vauchy, Eric Deconinck, et al.
Oncotarget
|
February 10, 2018
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
Francesco Saraceni, Myriam Labopin, Rose-Marie Hamladji, et al.
Transfusion
|
July 29, 2010
Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors
Caroline Marmier-Savet, Fabrice Larosa, Faezeh Legrand, et al.
Haematologica
|
March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation
Nicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
American Journal of Hematology
|
June 13, 2020
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
Arnon Nagler, Myriam Labopin, Jonathan Canaani, et al.
Leukemia
|
November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Blood
|
July 16, 2011
Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation
Fabrice Larosa, Eric Deconinck, Philippe Helias, et al.
American Journal of Hematology
|
July 8, 2018
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation
Maria H Gilleece, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
American Journal of Hematology
|
April 18, 2020
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)
Enrico Maffini, Myriam Labopin, Didier Blaise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2008
Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC
Patrice Chevallier, Mohamad Mohty, Bruno Lioure, et al.
Page
of 24